Annovis Bio, Inc.
NYSE: ANVS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Maria L. Maccecchini
- Employees
- 8
- Headquarters
- Malvern, United States
- IPO year
- 2020
- Market cap
- $33.4M
- Website
- https://www.annovisbio.com
Loading ANVS…
Loading profile data…Frequently asked questions about ANVS
What does Annovis Bio, Inc. (ANVS) do?
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinica...
Where does ANVS trade?
Annovis Bio, Inc. (ANVS) trades on the New York Stock Exchange.
What sector is ANVS in?
Annovis Bio, Inc. (ANVS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Annovis Bio, Inc.?
Maria L. Maccecchini is the chief executive officer of Annovis Bio, Inc. (ANVS).
Where is Annovis Bio, Inc. headquartered?
Annovis Bio, Inc. is headquartered in United States.
Does ANVS pay a dividend?
Annovis Bio, Inc. (ANVS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ANVS go public?
Annovis Bio, Inc. (ANVS) completed its initial public offering in 2020.